VALSARTAN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H29N5O3
Molecular Weight	435.5188
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCC(=O)N(CC1=CC=C(C=C1)C2=C(C=CC=C2)C3=NN=NN3)[C@@H](C(C)C)C(O)=O

InChI

InChIKey=ACWBQPMHZXGDFX-QFIPXVFZSA-N

InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C24H29N5O3
Molecular Weight	435.5188
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25052956http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021283s50lbl.pdfhttps://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/entresto.pdf
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19934029 https://www.ncbi.nlm.nih.gov/pubmed/26082640 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207620Orig1s000PharmR.pdf

LCZ696 contains equal molar amounts of valsartan and sacubitril (1:1 ratio). Sacubitril is a prodrug that is rapidly metabolized by enzymatic cleavage of the ethyl ester group into the biologically active neprilysin inhibitor, LBQ 657. Valsartan, a blocker of the angiotensin II type-1 receptor, is biologically active in its original form. FDA has approved ENTRESTO, previously known as LCZ696, for the treatment of heart failure with reduced ejection fraction.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Type-1 angiotensin II receptor 39 Target ID: CHEMBL227 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207620Orig1s000PharmR.pdf	Antagonist 2760	2.38 nM [Ki]
Neprilysin 28 Target ID: CHEMBL1944 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207620Orig1s000PharmR.pdf	Inhibitor 8228	2.3 nM [IC50]
Type-1 angiotensin II receptor 39 Target ID: CHEMBL227 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021283s50lbl.pdf	Blocker 534	2.43 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2565
Chronic heart failure with reduced ejection fraction 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207620Orig1s000lbl.pdf	Primary	Approved 8360	ENTRESTO Approved Use ENTRESTO is a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker, indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. ENTRESTO is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB. Launch Date 1.43614083E12
Hypertension 549 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021283s50lbl.pdf	Primary	Approved 8360	DIOVAN Approved Use Diovan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure (1.2) Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction (1.3) Launch Date 1.31086077E12
Heart failure 87 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021283s50lbl.pdf	Primary	Approved 8360	DIOVAN Approved Use Diovan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure (1.2) Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction (1.3) Launch Date 1.31086077E12
Myocardial infarction 104 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021283s50lbl.pdf	Palliative	Approved 8360	DIOVAN Approved Use Diovan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure (1.2) Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction (1.3) Launch Date 1.31086077E12

C_max

Value	Dose	Analyte	Population
2808 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27128457	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	VALSARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5756 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27128457	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	VALSARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.141 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21617777	160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered:	VALSARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
20650 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27128457	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	VALSARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
34310 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27128457	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	VALSARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
22.56 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21617777	160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered:	VALSARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
8.45 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27128457	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	VALSARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27128457	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	VALSARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
9.55 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21617777	160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered:	VALSARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
2.24 mg single, oral Overdose Dose: 2.24 mg Route: oral Route: single Dose: 2.24 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15222725	unknown, 25 years n = 1 Health Status: unknown Age Group: 25 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15222725	Other AEs: Muscle cramps... Other AEs: Muscle cramps (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15222725
640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17762658	unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: https://pubmed.ncbi.nlm.nih.gov/17762658	Disc. AE: Hyperkalemia... Other AEs: Dizziness, Headache... AEs leading to discontinuation/dose reduction: Hyperkalemia (1 patient) Other AEs: Dizziness (8.3%) Headache (9.2%) Back pain (5.8%) Upper respiratory tract infection (5.8%) Nasopharyngitis (5%) Diarrhea (5%) Hypoglycemia (5%) Peripheral edema (4.2%) Nausea (4.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/17762658
320 mg 1 times / day steady, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf https://pubmed.ncbi.nlm.nih.gov/15329835	pregnant Health Status: pregnant Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf https://pubmed.ncbi.nlm.nih.gov/15329835	Disc. AE: Disorder fetal... AEs leading to discontinuation/dose reduction: Disorder fetal Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf https://pubmed.ncbi.nlm.nih.gov/15329835
320 mg 1 times / day steady, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf	unhealthy n = 2316 Health Status: unhealthy Condition: hypertension Population Size: 2316 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf	Disc. AE: Headache, Dizziness... AEs leading to discontinuation/dose reduction: Headache (2.3%) Dizziness (2.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
320 mg 1 times / day steady, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf	unhealthy n = 2506 Health Status: unhealthy Condition: Heart Failure Population Size: 2506 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf	Disc. AE: Creatinine increased, Potassium increased... AEs leading to discontinuation/dose reduction: Creatinine increased (0.5%) Potassium increased (0.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf

AEs

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:9927	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9927
ChemicalBook	CB14657818	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB14657818
ChemicalBook	CB23133442	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB23133442
ChemicalBook	CB34813436	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB34813436
ChemicalBook	CB3952405	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3952405
ChemicalBook	CB6182539	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6182539
MolPort	MolPort-002-507-854	https://www.molport.com/shop/molecule-link/MolPort-002-507-854
MolPort	MolPort-003-666-608	https://www.molport.com/shop/molecule-link/MolPort-003-666-608
Selleck Chemicals	Valsartan(Diovan)	http://www.selleckchem.com/products/Valsartan(Diovan).html
ZINC	ZINC000003875259	http://zinc15.docking.org/substances/ZINC000003875259
eMolecules	1989469	https://www.emolecules.com/cgi-bin/more?vid=1989469
eMolecules	2724803	https://www.emolecules.com/cgi-bin/more?vid=2724803
eMolecules	32278148	https://www.emolecules.com/cgi-bin/more?vid=32278148
eMolecules	33507560	https://www.emolecules.com/cgi-bin/more?vid=33507560

PubMed

Title	Date	PubMed
Development and validation of chiral high-performance liquid chromatographic methods for the quantitation of valsartan and of the tosylate of valinebenzyl ester.	1996 Nov 8	8953194
LCZ696 : a new paradigm for the treatment of heart failure?	2015 Feb	25597387
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.	2016 Aug	26990595

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Wed Jul 05 23:56:35 UTC 2023` Edited by `admin` on `Wed Jul 05 23:56:35 UTC 2023`
Record UNII	80M03YXJ7I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VALSARTAN

Official Name

English

VALSARTAN COMPONENT OF COPALIA

Brand Name

English

COPALIA COMPONENT VALSARTAN

Brand Name

English

VALSARTAN COMPONENT OF VALTURNA

Common Name

English

L-VALINE, N-(1-OXOPENTYL)-N-((2'-(1H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-

Systematic Name

English

VALSARTAN [VANDF]

Common Name

English

VALSARTAN COMPONENT OF EXFORGE HCT

Common Name

English

BYVALSON COMPONENT OF VALSARTAN

Common Name

English

IMPRIDA-HCT COMPONENT VALSARTAN

Brand Name

English

NSC-758927

Code

English

CGP 48933

Code

English

DIOVAN HCT COMPONENT VALSARTAN

Common Name

English

VALSARTAN [EMA EPAR]

Common Name

English

VALSARTAN [MI]

Common Name

English

VALSARTAN [USP MONOGRAPH]

Common Name

English

VALTURNA COMPONENT VALSARTAN

Brand Name

English

VALSARTAN [USAN]

Common Name

English

VALSARTAN [ORANGE BOOK]

Common Name

English

VALSARTAN [EP IMPURITY]

Common Name

English

VALSARTAN [MART.]

Common Name

English

VALSARTAN COMPONENT OF IMMPRIDA

Brand Name

English

VALSARTAN COMPONENT OF DIOVAN HCT

Common Name

English

Valsartan [WHO-DD]

Common Name

English

EXFORGE COMPONENT VALSARTAN

Brand Name

English

VALSARTAN COMPONENT OF EXFORGE

Brand Name

English

DIOVAN

Brand Name

English

DAFIRO COMPONENT VALSARTAN

Brand Name

English

VALSARTAN [HSDB]

Common Name

English

VALSARTAN COMPONENT OF ENTRESTO

Brand Name

English

AGSAV301 COMPONENT VALSARTAN

Common Name

English

COPALIA-HCT COMPONENT VALSARTAN

Brand Name

English

EXFORGE HCT COMPONENT VALSARTAN

Common Name

English

VALSARTAN [USP-RS]

Common Name

English

VALSARTAN [JAN]

Common Name

English

VALSARTAN COMPONENT OF DAFIRO-HCT

Brand Name

English

VALSARTAN COMPONENT OF COPALIA-HCT

Brand Name

English

VALSARTAN COMPONENT OF BYVALSON

Common Name

English

ENTRESTO COMPONENT VALSARTAN

Brand Name

English

VALSARTAN [EP MONOGRAPH]

Common Name

English

PREXXARTAN

Brand Name

English

IMPRIDA COMPONENT VALSARTAN

Brand Name

English

valsartan [INN]

Common Name

English

VALSARTAN COMPONENT OF IMPRIDA-HCT

Brand Name

English

DAFIRO-HCT COMPONENT VALSARTAN

Brand Name

English

N-(P-(O-1H-TETRAZOL-5-YLPHENYL)BENZYL)-N-VALERYL-L-VALINE

Common Name

English

CGP-48933

Code

English

Classification Tree Code System Code

WHO-ATC

C09CA03

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

EMA ASSESSMENT REPORTS

IMPRADA-HCT (WITHDRAWN: HYPERTENSION)

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

WHO-ATC

C10BX10

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

EMA ASSESSMENT REPORTS

EXFORGE (AUTHORIZED: HYPERTENSION)

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

FDA ORPHAN DRUG

494115

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

WHO-VATC

QC09CA03

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

NDF-RT

N0000175561

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

WHO-ATC

C09DX02

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

EMA ASSESSMENT REPORTS

COPALIA (AUTHORIZED: HYPERTENSION)

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

WHO-ATC

C09DX01

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

WHO-VATC

QC09DA03

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

EMA ASSESSMENT REPORTS

EXFORGE-HCT (AUTHORIZED: HYPERTENSION)

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

NCI_THESAURUS

C66930

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

WHO-ATC

C09DB08

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

EMA ASSESSMENT REPORTS

DARFIRO-HCT (AUTHORIZED: HYPERTENSION)

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

LIVERTOX

NBK547944

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

EMA ASSESSMENT REPORTS

COPALIA-HCT (AUTHORIZED: HYPERTENSION)

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

WHO-ATC

C09DA03

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

NDF-RT

N0000000070

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

EMA ASSESSMENT REPORTS

DAFIRO (AUTHORIZED: HYPERTENSION)

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

WHO-VATC

QC09DX01

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

EMA ASSESSMENT REPORTS

IMPRIDA (AUTHORIZED: HYPERTENSION)

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

WHO-ATC

C09DX05

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

WHO-ATC

C09DX04

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

WHO-VATC

QC09DX02

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

WHO-ATC

C09DB01

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

WHO-VATC

QC09DB01

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

Code System Code Type Description

NSC

758927

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

PRIMARY

DAILYMED

80M03YXJ7I

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

PRIMARY

INN

7016

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

PRIMARY

RXCUI

69749

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

PRIMARY

RxNorm

CAS

137862-53-4

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

PRIMARY

IUPHAR

3937

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

PRIMARY

ChEMBL

CHEMBL1069

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

PRIMARY

FDA UNII

80M03YXJ7I

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

PRIMARY

MESH

C081489

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

PRIMARY

WIKIPEDIA

VALSARTAN

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

PRIMARY

SMS_ID

100000088000

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

PRIMARY

RS_ITEM_NUM

1708762

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

PRIMARY

HSDB

7519

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

PRIMARY

EPA CompTox

DTXSID6023735

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

PRIMARY

DRUG BANK

DB00177

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

PRIMARY

NCI_THESAURUS

C47781

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

PRIMARY

LACTMED

Valsartan

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

PRIMARY

DRUG CENTRAL

2806

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

PRIMARY

CHEBI

9927

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

PRIMARY

USAN

HH-50

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

PRIMARY

MERCK INDEX

M11372

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

PRIMARY

Merck Index

PUBCHEM

60846

Created by admin on Wed Jul 05 23:56:36 UTC 2023 , Edited by admin on Wed Jul 05 23:56:36 UTC 2023

PRIMARY

EVMPD

SUB00017MIG

Created by admin on Wed Jul 05 23:56:35 UTC 2023 , Edited by admin on Wed Jul 05 23:56:35 UTC 2023

PRIMARY

Related Record Type Details


					ZWJ2Y6JZWY

OAT-3

TRANSPORTER -> INHIBITOR


					91L39G324W

PEPT-2

TRANSPORTER -> INHIBITOR


					056QD38ZSG

TYPE-1 ANGIOTENSIN II RECEPTOR

TARGET -> INHIBITOR


					XYD5147M6H

PEPT-1

TRANSPORTER -> INHIBITOR


					WB8FT61183

SACUBITRIL VALSARTAN SODIUM HYDRATE

SALT/SOLVATE -> PARENT


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					80M03YXJ7I

VALSARTAN

BASIS OF STRENGTH->SUBSTANCE

Interaction Type:

ASSAY (HPLC)

Qualification:

USP

Amount:


					80M03YXJ7I

VALSARTAN

BASIS OF STRENGTH->SUBSTANCE

Interaction Type:

ASSAY (TITRATION)

Qualification:

EP

Amount:


					AIN96D6SGL

OATP1B1

TRANSPORTER -> INHIBITOR


					D6XN347U2D

VALSARTAN MONOSODIUM

SALT/SOLVATE -> PARENT

Amount:


					4HZ67LW8L7

OAT-4

TRANSPORTER -> INHIBITOR


					I81U7H57XI

OAT-1

TRANSPORTER -> INHIBITOR


					U55M6YDH5T

VALSARTAN DISODIUM

SALT/SOLVATE -> PARENT

Amount:

Related Record Type Details


					N891C54AXX

VALERYL-4-HYDROXYVALSARTAN

METABOLITE INACTIVE -> PARENT


					N891C54AXX

VALERYL-4-HYDROXYVALSARTAN

METABOLITE INACTIVE -> PARENT

Comments:

Valsartan was metabolized to a small extent only. The only notable metabolite in plasma, urine and faecs

Interaction Type:

MAJOR

Qualification:

FECAL; PLASMA; URINE

Related Record Type Details


					2P0MPU907C

VALSARTAN BENZYL ESTER

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					13EG6HX8ND

METHYL N-((2'-CYANO(1,1'-BIPHENYL)-4-YL)METHYL)-L-VALINATE

IMPURITY -> PARENT


					3IQ78TTX1A

N-NITROSODIETHYLAMINE

IMPURITY -> PARENT

Comments:

Probable human carcinogen.

Amount:


					2P0MPU907C

VALSARTAN BENZYL ESTER

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Qualification:

EP


					IDC67444MI

VALSARTAN, D-

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					H81CGI9K6Z

BENZYL(METHYL)NITROSAMINE

IMPURITY -> PARENT

Comments:

Priority toxic pollutant.

Amount:


					6X37Q93CWN

N-((2'-CYANO(1,1'-BIPHENYL)-4-YL)METHYL)-N-(1-OXOPENTYL)-L-VALINE METHYL ESTER

IMPURITY -> PARENT


					4GS9P3LL2L

DESPENTANOYL BUTANOYL VALSARTAN

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					4GS9P3LL2L

DESPENTANOYL BUTANOYL VALSARTAN

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					7BZQ418Z0J

N-(1-OXOPENTYL)-N-((2'-(2H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-L-VALINE METHYL ESTER

IMPURITY -> PARENT


					IDC67444MI

VALSARTAN, D-

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					KH72U7Q76E

2-(N-((2'-CYANO-(1,1'-BIPHENYL)-4-YL)METHYL)PENTANAMIDO)-3-METHYLBUTANOIC ACID, (2S)-

IMPURITY -> PARENT


					M43H21IO8R

N-NITROSODIMETHYLAMINE

IMPURITY -> PARENT

Comments:

NDMA is an organic chemical that is in a family of potent carcinogens.

Amount:

Related Record Type Details


					80M03YXJ7I

VALSARTAN

ACTIVE MOIETY

Name	Property Type	Parameters
Volume of Distribution	PHARMACOKINETIC

Route of Elimination	PHARMACOKINETIC	ROUTE OF ADMINISTRATION: ORAL

MAXIMUM TOLERATED DOSE	TOXICITY

PROTEIN BINDING	PHARMACOKINETIC

Route of Elimination	PHARMACOKINETIC	ROUTE OF ADMINISTRATION: ORAL

RENAL CLEARANCE	PHARMACOKINETIC

Biological Half-life	PHARMACOKINETIC

AE	Significance	Dose	Population
Muscle cramps	1 patient	2.24 mg single, oral Overdose Dose: 2.24 mg Route: oral Route: single Dose: 2.24 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15222725	unknown, 25 years n = 1 Health Status: unknown Age Group: 25 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15222725
Hyperkalemia	1 patient Disc. AE	640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17762658	unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: https://pubmed.ncbi.nlm.nih.gov/17762658
Nausea	4.2%	640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17762658	unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: https://pubmed.ncbi.nlm.nih.gov/17762658
Peripheral edema	4.2%	640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17762658	unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: https://pubmed.ncbi.nlm.nih.gov/17762658
Diarrhea	5%	640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17762658	unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: https://pubmed.ncbi.nlm.nih.gov/17762658
Hypoglycemia	5%	640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17762658	unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: https://pubmed.ncbi.nlm.nih.gov/17762658
Nasopharyngitis	5%	640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17762658	unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: https://pubmed.ncbi.nlm.nih.gov/17762658
Back pain	5.8%	640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17762658	unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: https://pubmed.ncbi.nlm.nih.gov/17762658
Upper respiratory tract infection	5.8%	640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17762658	unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: https://pubmed.ncbi.nlm.nih.gov/17762658
Dizziness	8.3%	640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17762658	unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: https://pubmed.ncbi.nlm.nih.gov/17762658
Headache	9.2%	640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17762658	unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: https://pubmed.ncbi.nlm.nih.gov/17762658
Disorder fetal	Disc. AE	320 mg 1 times / day steady, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf https://pubmed.ncbi.nlm.nih.gov/15329835	pregnant Health Status: pregnant Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf https://pubmed.ncbi.nlm.nih.gov/15329835
Dizziness	2.3% Disc. AE	320 mg 1 times / day steady, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf	unhealthy n = 2316 Health Status: unhealthy Condition: hypertension Population Size: 2316 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
Headache	2.3% Disc. AE	320 mg 1 times / day steady, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf	unhealthy n = 2316 Health Status: unhealthy Condition: hypertension Population Size: 2316 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
Creatinine increased	0.5% Disc. AE	320 mg 1 times / day steady, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf	unhealthy n = 2506 Health Status: unhealthy Condition: Heart Failure Population Size: 2506 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
Potassium increased	0.5% Disc. AE	320 mg 1 times / day steady, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf	unhealthy n = 2506 Health Status: unhealthy Condition: Heart Failure Population Size: 2506 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf

Details

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

AEs

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2